Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp, who is also a director, reported selling 3,828 shares of common stock on January 22, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025, which is designed to allow insiders to trade on a scheduled basis. The shares were sold at a weighted average price of $18.1024, with individual trade prices ranging from $18.00 to $18.19. Following this transaction, Cohlhepp directly beneficially owns 210,164 shares of Bicara common stock.
Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan reported an option exercise and matching share sale on January 22, 2026. Ivan exercised a stock option for 1,882 shares of common stock at $3.7898 per share, then sold 1,882 common shares at a weighted average price of $18.1522 under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. Following these transactions, Ivan directly holds 145,355 shares of common stock and 65,462 stock options. The option underlying the exercised shares vests in sixteen equal quarterly installments following April 5, 2023, subject to continued service.
BCAX insider Ryan Cohlhepp has filed a Form 144 notice to sell 3,828 shares of the company’s common stock through UBS Financial Services, Inc. on or about January 22, 2026 on the NASDAQ market. The planned sale has an aggregate market value of 64,961.16 based on the figures reported. These shares were acquired on May 12, 2024 by exercising a stock option from the issuer for cash.
The filing also lists prior sales of BCAX common stock by Cohlhepp during the past three months, including 12,500 shares sold on October 15, 2025 for gross proceeds of 226,942.50 and additional 12,500-share blocks in November and December 2025, plus a smaller sale on January 15, 2026. The notice includes a representation that the seller is not aware of undisclosed material adverse information about the issuer.
BCAX insider Ivan Hyep has filed a Form 144 notice to sell 1,882 shares of common stock through UBS Financial Services, Inc., with an aggregate market value of $34,158.30 on NASDAQ around 01/22/2026. These shares were acquired the same day via a cash exercise of stock options from the issuer. The filing notes that 54,781,950 shares of this class were outstanding. Over the past three months, the same seller reported additional BCAX common stock sales totaling several thousand shares, with gross proceeds including $168,491.56, $10,980.75, and $330,093.69.
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp, who also serves as a director, reported a small open-market sale of company stock. On January 15, 2026, he sold 149 shares of Common Stock at a price of $18.02 per share, coded as a sale transaction. After this trade, he beneficially owned 213,992 shares of Bicara Therapeutics Common Stock in direct ownership form. The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that was adopted on February 12, 2025, indicating it was pre-arranged under SEC rules.
BCAX insider Ryan Cohlhepp filed a Rule 144 notice to sell 149 shares of the company’s common stock through UBS Financial Services on or around 01/15/2026, with an aggregate market value of $2,684.98. The filing reports that these shares were acquired on 05/12/2024 by exercising a stock option for cash. The notice indicates total common shares outstanding of 54,781,950, showing this planned sale is very small relative to the company’s share base.
Over the prior three months, Cohlhepp sold additional common shares in three equal blocks of 12,500 shares each on 10/15/2025, 11/21/2025, and 12/15/2025, with reported gross proceeds of $226,942.50, $225,587.50, and $233,547.50, respectively. The signer represents that he does not know of any undisclosed material adverse information about BCAX at the time of this notice.
Bicara Therapeutics Inc. filed a Form 8-K to report that it issued a press release on January 12, 2026 titled “Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook.”
The company states that this press release is furnished as Exhibit 99.1 and incorporated by reference, indicating it contains details on the chosen Phase 3 dose and management’s outlook for 2026.
Bicara Therapeutics Inc. disclosed that its Chief Executive Officer and director exercised stock options and acquired common shares. On 12/16/2025, the reporting person exercised a stock option and acquired 29,500 shares of common stock at an exercise price of $5.4537 per share. After this transaction, the reporting person beneficially owned 339,392 shares of common stock directly.
The exercised option was part of a larger grant of stock options with an exercise price of $5.4537, originally covering shares of common stock and expiring on 12/14/2033. Following the reported transaction, the reporting person held 565,512 stock options directly. The option grant vests in sixteen equal quarterly installments following December 14, 2023, subject to the reporting person’s continued service.
Bicara Therapeutics reported insider transactions by its President and COO, who is also a director. On December 15, 2025, the insider exercised stock options for 8,000 shares of common stock at an exercise price of $3.7898 per share and, in separate trades, sold 8,000 and 4,500 shares of common stock at a weighted average price of $18.6838 per share under a Rule 10b5-1 trading plan adopted on February 12, 2025.
After these transactions, the insider directly owned 189,141 shares of Bicara common stock and held 141,334 stock options. The option covers 8,000 underlying shares in this transaction, carries a $3.7898 exercise price, expires on August 8, 2033, and vests in sixteen equal quarterly installments following August 8, 2023, subject to continued service.
Bicara Therapeutics Inc. is launching an at-the-market offering of up to $150,000,000 of its common stock through TD Securities (USA) LLC (TD Cowen) as sales agent. Shares may be sold from time to time on The Nasdaq Global Market under the symbol BCAX, in negotiated transactions or other methods deemed to be at-the-market offerings, with TD Cowen earning a commission of up to 3.0% of gross proceeds.
Bicara is a clinical-stage biopharmaceutical company focused on bifunctional antibodies for solid tumors. Its lead program, ficerafusp alfa, is in a pivotal Phase 2/3 trial in head and neck squamous cell carcinoma, following Phase 1/1b data showing a 54% objective response rate and 21.3‑month median overall survival in an efficacy-evaluable HPV‑negative population. Net proceeds are expected to support research and clinical development, commercialization preparation, expansion of R&D programs, and general corporate purposes.